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Eanolazine Is Effective
or Acute or Chronic Ischemic
ysfunction With Heart Failure
e congratulate Morrow et al. (1) for their interesting study on the effects
f ranolazine in patients with non–ST-segment elevation myocardial
nfarction. Ranolazine reduced the composite primary end point of
ardiovascular death, myocardial infarction, and recurrent ischemia in
atients with B-type natriuretic peptide 80 pg/ml. Interestingly, there
as a decrease in composite arrhythmia end points consisting of ventric-
lar tachycardia (100 beats/min for 3 beats), supraventricular tachy-
ardia (120 beats/min for4 beats), and bradycardia (40 beats/min,
ause 2.5 s or 3o atrioventricular block). Ranolazine usage showed a
rend toward reduction across all arrhythmia types: ventricular tachycardia
p 0.13), supraventricular tachycardia (p 0.001), atrial fibrillation
p  0.4), and sudden cardiac death (p  0.11). These effects were
bserved over a mean duration of 343 days.
We recently reported successful use of ranolazine in a patient with
hronic ischemic cardiomyopathy, symptomatic premature ventricular
omplexes (PVC [36% of all beats]), and monomorphic ventricular
achycardia who had failed amiodarone and mexilitine therapy.
anolazine decreased the total number of PVCs to 1% to 2% of all
eats, eliminated the ventricular tachycardia, and led to complete
esolution of symptoms (2).
Inhibition of the late sodium current (INa) is the proposed
echanism of both the anti-ischemic and anti-arrhythmic benefits of
anolazine. Activity in late INa activity is increased significantly in
schemia as well as congestive heart failure (3). Increased late INa
ctivity produces higher intracellular sodium, which results in calcium
verload through the sodium-calcium exchange. Ranolazine inhibits
ate INa 10-fold more selectively than peak INa. This mechanism,
long with its 1, 2, and calcium-channel antagonism, produces its
nti-ischemic and antiarrhythmic benefits (3).
The present study shows beneficial effects of ranolazine in the setting
f acute ischemia with evidence of heart failure. Our patient had a chronic
schemic cardiomyopathy with severe myocardial dysfunction (ejection
raction 15%) for which ranolazine produced excellent symptomatic relief.
uture studies using ranolazine are needed to evaluate patients with acute
nd chronic ischemia in the presence of elevated B-type natriuretic
eptide/left ventricular dysfunction to further clarify its benefits. It
ay be this category of patients who have the highest risk–benefit
atio from ranolazine therapy.
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e appreciate the compliment and additional perspective from
r. Nanda and colleagues regarding our paper (1). Patients with
schemic heart disease and left ventricular dysfunction, such as the
atient described by Dr. Nanda and colleagues, are at substantial
isk of major cardiovascular events, including sudden cardiac death.
oreover, they are at higher risk of proarrhythmia than patients
ith normal left ventricular function with multiple classes of
ntiarrhythmic medications, and they may poorly tolerate anti-
schemic medications with negative inotropic effects. We have also
bserved that patients with elevated levels of B-type natriuretic
eptide are at particularly high risk of sudden cardiac death, even
fter accounting for left ventricular ejection fraction (2).
In pre-clinical studies, ranolazine has shown potentially favor-
ble electrophysiological effects, such as a decrease in dispersion of
epolarization, a reduction in action potential duration, and sup-
ression of early after-depolarizations (3). In addition, in animal
odels of heart failure, ranolazine improves contractile function
mmediately after acute ischemia (4) and left ventricular ejection
raction in the setting of chronic ischemic heart failure (5).
We have shown previously that in patients with unstable ischemic
eart disease, ranolazine significantly reduces the risk of ventricular
nd supraventricular tachycardia (3). Notably, we have also found that
hese effects on arrhythmias are present in patients at higher risk for
achyarrhythmia, such as those with elevated B-type natriuretic
eptide (1) or a history of left ventricular dysfunction (3). These
ndings are consistent with the observations described by Dr. Nanda
nd colleagues. On the basis of these collective findings, we agree that
he investigation of ranolazine in patients with ischemic heart disease
nd left ventricular dysfunction would be of substantial interest.
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re Angiotensin-Converting
nzyme Inhibitors and
eta-Blockers Ineffective in
hildren With Dilated
ardiomyopathy and
eart Failure?
n a retrospective, single-center study of children with dilated
ardiomyopathy, Kantor et al. (1) compared outcomes in children
reated with 3 different heart failure regimens (digoxin alone,
igoxin and angiotensin-converting enzyme inhibitors [ACEI] but
ot beta-blockers [BB], and ACEI-BB combination) in a cohort
f 189 patients. Because the study cohort represents their 30-year
xperience with dilated cardiomyopathy and different treatment
egimens, the allocation to treatment groups was determined by
he era of presentation and guided by the prevailing standards in
dult heart failure therapy. On the basis of their observation that
he transplantation-free survival time was similar among the 3
roups, the authors question whether evolving pharmacologic
reatments for heart failure are as effective in improving survival in
hildren with heart failure as they are in adults. Because ACEI and
B drugs are routinely used in pediatric heart failure, a closer
xamination of their analysis is important.
Unfortunately, there are at least 2 reasons to question the
alidity of their findings. Because the study center became a major
eferral center for heart transplantation halfway through the study,
election bias combined with selection of a composite end point
ikely biases the results toward the null. The more recent patients
those in the ACEI and ACEI-BB groups) are more likely to be
hose referred for heart transplantation and thus likely to have
ore severe heart failure. The similarity in ejection fraction amonghe 3 groups is not by itself compelling enough to eliminate this pelection bias. Second, because the primary end point is a time-
o-event composite outcome for death or transplantation, it
hanges halfway through the study when viewed from a clinical
erspective. It is notable that almost all patients who reached the
rimary end point in the digoxin-only group died, whereas most
atients in the ACEI and ACEI-BB groups reached the primary
nd point by receiving a heart transplant. Because the waiting list
urvival time without a transplant is highly variable and may be
ears in some patients listed for heart failure on oral heart failure
herapy (those listed as Status 2 in the U.S. on the United Network
f Organ Sharing wait list), transplantation could have artificially
hortened the time-to-event outcome for several patients in the
CEI and ACEI-BB groups.
In randomized clinical trials, the comparison groups are similar
n baseline characteristics, and the outcome difference can be
ttributed to the study drug alone. Moreover, the primary end
oint remains the same during the entire study duration. We
ecognize that it has been particularly difficult to conduct random-
zed clinical trials in children with heart failure because of the small
umber of children with heart failure. The largest randomized trial
f a heart failure therapy in children was able to enroll only 161
hildren from 26 centers over a 4-year period of recruitment and
as even then considered potentially underpowered by the authors
o detect outcome differences (2). The difficulty in conducting
arge controlled trials in children with heart failure makes obser-
ational studies important. This study highlights the significant
hallenges faced by investigators with an observational study
esign.
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rs. Singh and Almond engage in some useful conjecture, but
heir argument is not supported by published data, including our
wn (1). Much of their argument revolves around the possible
nterdependence of the choice for angiotensin-converting enzyme
nhibitor (ACEI)/beta-blocker therapy and the selection bias for
ransplantation in “sicker” patients who may have been on these
herapies. They speculate that the bias to perform transplantation
n sicker patients undergoing treatment with ACEI/beta-blocker
herapy artificially and negatively skewed the survival of these
atients with the arrival of the transplant era.
